|
Market Closed -
Nasdaq
16:00:00 2026-09-28 EDT
|
5-day change | 1st Jan Change | ||
| 3.650 USD | -8.98% |
|
-11.84% | +157.04% |
| 08-19 | Edesa Biotech Launches Public Offering of Common Shares, Warrants | MT |
| 08-13 | Edesa Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 | CI |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
| 16.33 | +307.32% | 3 | |||||||
| 187.07 | +15.19% | 18 | |||||||
| 1,175.3 | +22.02% | 15 | |||||||
| 49.73 | +9.85% | 24 | |||||||
| 199.04 | +68.92% | 23 | |||||||
| 103.07 | +18.94% | 20 | |||||||
| 2,453.79 | +7.76% | 15 | |||||||
| 1,397.26 | +20.98% | 8 | |||||||
| 53.69 | -7.69% | 16 | |||||||
| 619.67 | +32.69% | 19 | |||||||
| 21.61 | +83.3% | 13 | |||||||
| 682.11 | +32.05% | 18 | |||||||
| 133.02 | +66.15% | 21 | |||||||
| 107.23 | +62.67% | 13 | |||||||
| 109.9 | +69.97% | 20 | |||||||
| 12.75 | +51.07% | 4 | |||||||
| 109 | +93.92% | 9 | |||||||
| 100.11 | +60.46% | 16 | |||||||
| 120.08 | +40.13% | 13 | |||||||
| - | - | - | - | - | |||||
| Average | 402.67 | +55.56% | 15 | ||||||
| Weighted average by Cap. | 523.76 | +30.90% | 17 |
- Stock Market
- Stocks
- EDSA Stock
- Sector Edesa Biotech, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
















